Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
Eur J Cardiovasc Nurs ; 22(4): 425-429, 2023 05 25.
Article in English | MEDLINE | ID: mdl-36149870

ABSTRACT

AIMS: Atrial fibrillation (AF) is the most prevalent cardiac arrhythmia worldwide, with a significant impact on morbidity, mortality, and utilization of healthcare resources. Electrical direct-current cardioversion (DCCV) is offered to patients with ongoing symptoms despite medical management. In this study, we aim to evaluate the safety and efficacy of a specialized nurse-led DCCV service. METHODS AND RESULTS: This was a retrospective cohort study analysing the outcome of patients presenting with AF or flutter, who were subsequently referred for a nurse-led DCCV procedure between August 2017 and December 2019. Analysis included a total of 341 patients (mean age = 68.37; standard deviation = 10.96) who presented with either AF (N = 267; 78.30%) or atrial flutter (N = 74; 21.70%). Approximately 30% of patients were females (N = 101) and 70% were males (N = 240). Of the 341 patients who underwent DCCV, 299 were successfully cardioverted (87.68%). Of those patients successfully cardioverted, 167 remained in sinus rhythm after 6 weeks (55.85%); 93 patients reverted back to AF (31.10%). Thirty-eight patients were lost to follow up (12.71%). Of all 341 patients who underwent DCCV, only 24 patients were admitted to hospital during the subsequent 3-month period (7.04%). Importantly, no patients were admitted as a direct complication of the DCCV procedure. CONCLUSION: Overall, data gathered from this study provides positive evidence to support the use of a nurse-led DCCV service. In addition to obtaining very successful cardioversion rates, we found low remission rates, with a very low hospital readmission rate for AF-related issues after successful DCCV.


Subject(s)
Atrial Fibrillation , Female , Male , Humans , Aged , Atrial Fibrillation/therapy , Electric Countershock/adverse effects , Nurse's Role , Retrospective Studies , Hospitalization
2.
BMJ Case Rep ; 14(9)2021 Sep 23.
Article in English | MEDLINE | ID: mdl-34556531

ABSTRACT

Vaccine-induced immune thrombotic thrombocytopenia (VITT) is a relatively novel term which describes patients who have developed a low platelet count and prothrombotic tendencies secondary to receiving a vaccine. The concept has been derived from the well-established phenomenon of heparin-induced thrombocytopenia, and several cases of VITT have now been reported in patients who have received the AstraZeneca (ChAdOx1 nCov-19) vaccine. Unfortunately, some of these patients have gone on to develop intracranial venous sinus thrombosis. We present a case of VITT-associated sinus thrombosis secondary to the AstraZeneca (ChAdOx1 nCov-19) vaccine, which was complicated by a large intracerebral haemorrhage.


Subject(s)
COVID-19 , Sinus Thrombosis, Intracranial , Vaccines , COVID-19 Vaccines , ChAdOx1 nCoV-19 , Humans , Intracranial Hemorrhages/chemically induced , Intracranial Hemorrhages/diagnostic imaging , SARS-CoV-2 , Sinus Thrombosis, Intracranial/chemically induced , Sinus Thrombosis, Intracranial/diagnostic imaging
3.
Cureus ; 13(9): e17913, 2021 Sep.
Article in English | MEDLINE | ID: mdl-34660108

ABSTRACT

Like many other countries at the moment, the United Kingdom (UK) is currently under national lockdown due to the coronavirus disease 2019 (COVID-19) pandemic. An unfortunate consequence of such social isolation measures is that patients with genuine acute medical emergencies may not present to a hospital in a timely manner. We present such a scenario, whereby a patient had a delayed presentation of ST-elevation myocardial infarction (STEMI) due to fear of breaching COVID-19 lockdown rules. As a result of the patient presenting well outside the optimal treatment window, her STEMI was complicated by a severe ventricular septal defect (VSD). We discuss how the COVID-19 pandemic has influenced the nature and management of STEMIs and associated issues.

4.
BMJ Case Rep ; 14(7)2021 Jul 26.
Article in English | MEDLINE | ID: mdl-34312123

ABSTRACT

Coined in 1961 by Hirsch and Helwig, the term chondroid syringoma refers to a rare mixed tumour of subcutaneous tissue. Histologically, these tumours are almost identical to pleomorphic adenomas, arising from salivary glands. With the obvious difference being the presence of sweat gland tissue (syringoma) within a matrix of cartilage (chondroid). These mixed tumours remain scarce throughout the world, with an incidence of less than 0.098%. The vast majority of cases are reported in middle-aged and older adults, where they typically present as painless swellings in the head and neck, which gradually grow in size.


Subject(s)
Adenoma, Pleomorphic , Myoepithelioma , Sweat Gland Neoplasms , Adenoma, Pleomorphic/diagnostic imaging , Adenoma, Pleomorphic/surgery , Aged , Child , Head , Humans , Male , Middle Aged , Neck , Sweat Gland Neoplasms/diagnosis , Sweat Gland Neoplasms/surgery
5.
SELECTION OF CITATIONS
SEARCH DETAIL